| |
Maintenance group (n = 70)
|
Switch group (n = 78)
|
|---|
|
Number
|
%
|
Number
|
%
|
|---|
|
All AEs
|
49
|
70.0
|
55
|
70.5
|
|
All ADRs
|
20
|
28.6
|
26
|
33.3
|
|
Serious AEs
|
6
|
8.6
|
8
|
10.3
|
|
Serious ADRs
|
3
|
4.3
|
4
|
5.1
|
|
Any AEs leading to discontinuation
|
1
|
1.4
|
3
|
3.8
|
|
Any AEs leading to temporary drug interruption
|
13
|
18.6
|
8
|
10.3
|
|
AEs experienced by ≥ 5% of patients in either group (by preferred term)
|
|
Upper respiratory tract infection
|
4
|
5.7
|
9
|
11.5
|
|
Nasopharyngitis
|
7
|
10.0
|
4
|
5.1
|
|
Arthralgia
|
3
|
4.3
|
8
|
10.3
|
|
Cough
|
3
|
4.3
|
4
|
5.1
|
|
Active tuberculosis
|
0
|
0
|
0
|
0
|
|
Injection site reaction
|
1
|
1.4
|
5
|
6.4
|
- ADR adverse drug reaction, AE adverse event
